Citations

Clear

26 citation(s) found for "Sun, Chen".

Dataset for reporting of thymic epithelial tumours: recommendations from the International Collaboration on Cancer Reporting (ICCR)
Detterbeck, Frank, Marx, Alexander , Roden, Anja C. , Marchevsky, Alberto M. , Mukai, Kiyoshi , Marino, Mirella , Bakker, Michael A. den , Yang, Woo‐Ick, Judge, Meagan , Hirschowitz, Lynn, Nicholson, Andrew G. , Chen, Gang

Mayo Clinic

Histopathology | October 14, 2016 | Volume: 70 | Issue: 4 | Pages: 522-538

10.1111/his.13099 | PMID 27735079 Get It

AimsThe International Collaboration on Cancer Reporting (ICCR) is a not‐for‐profit organization formed by the Royal Colleges of Pathologists of Australasia and the United Kingdom, the College of American Pathologists, the Canadian Association of Pathologists–Association Canadienne des Pathologists in association with the Canadian Partnership Against Cancer, and the European Society of Pathology. Its goal is to produce standardized, internationally agreed, evidence‐based datasets for use throughout the world.Methods and resultsThis article describes the development of a cancer dataset by the multidisciplinary ICCR expert panel for the reporting of thymic epithelial tumours. The dataset includes ‘required’ (mandatory) and ‘recommended’ (non‐mandatory) elements, which are validated by a review of current evidence and supported by explanatory text. Seven required elements and 12 recommended elements were agreed by the international dataset authoring committee to represent the essential information for the reporting of thymic epithelial tumours.ConclusionsThe use of an internationally agreed, structured pathology dataset for reporting thymic tumours provides all of the necessary information for optimal patient management, facilitates consistent and accurate data collection, and provides valuable data for research and international benchmarking. The dataset also provides a valuable resource for those countries and institutions that are not in a position to develop their own datasets.
Inhibition of EZH2 by chemo- and radiotherapy agents and small molecule inhibitors induces cell death in castration-resistant prostate cancer
Wu, Changping , Jin, Xin , Yang, Yinhui , He, Yundong , Ding, Liya , Pan, Yunqian , Yang, H. J. , Chen, Shuai , Jiang, Jingting , Huang, Haojie , Jin, Xin

Mayo Clinic

Oncotarget | December 9, 2015 | Volume: 7 | Issue: 3 | Pages: 3440-3452

10.18632/oncotarget.6497 | PMID 26657505 Get It

Inflammation negatively regulates FOXP3 and regulatory T-cell function via DBC1
Gao, Yayi , Tang, Jiayou , Li, Qiang , Nie, Jia , Lin, Fang , Wu, Qingsi, Chen, Zuojia , Gao, Zhimei, Fan, Huimin , Tsun, Andy , Shen, Jijia, Chen, Guihua , Liu, Zhongmin , Olsen, Nancy J. , Zheng, Song Guo , Li, Bin , Chen, Weiqian , Lou, Zhenkun

Mayo Clinic

Proceedings of the National Academy of Sciences | June 10, 2015 | Volume: 112 | Issue: 25 | Pages: No page available

10.1073/pnas.1421463112 | PMID 26060310 Get It

Significance Treg cells suppress excessive and aberrant immune responses. Impaired function or homeostasis of Treg cells would induce severe autoimmune and inflammatory diseases. Forkhead box P3 (FOXP3), as a master regulator of Treg cells, forms a large complex with other binding factors to modulate Treg-cell function subtly in pathological and physiological conditions. We identified that Deleted in breast cancer 1 (DBC1) is an essential subunit of the FOXP3 complex in human CD4 + Treg cells. Our results show that the inflammatory cytokines TNF-α or IL-6 trigger FOXP3 degradation, whereas downregulation of DBC1 expression prevents FOXP3 degradation and maintains Treg-cell function under inflammatory stimuli in vitro and in vivo. These findings unveil a previously unidentified pathway for therapeutically modulating FOXP3 + Treg-cell stability under inflammation.
Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study
Chen, Minshan , Colombo, M., Roberts, Lewis R. , Schwartz, Myron , Chen, Pei‐Jer , Kudo, Masatoshi , Wagner, Samuel , Orsini, Lucinda, Sherman, Morris , Park, Joong‐Won , Johnson, Philip J. , Roberts, Lewis R , Kudo, Masatoshi

Mayo Clinic

Liver International | March 5, 2015 | Volume: 35 | Issue: 9 | Pages: 2155-2166

10.1111/liv.12818 | PMID 25752327 Get It

Abstract Background & Aims Hepatocellular carcinoma ( HCC ) is the second most common cause of cancer deaths worldwide. The global HCC BRIDGE study was a multiregional, large‐scale, longitudinal cohort study undertaken to improve understanding of real‐life management of patients with HCC , from diagnosis to death. Methods Data were collected retrospectively from January 2005 to September 2012 by chart reviews of eligible patients newly diagnosed with HCC at participating institutions. Results Forty‐two sites in 14 countries contributed final data for 18 031 patients. Asia accounted for 67% of patients, Europe for 20% and North America for 13%. As expected, the most common risk factor was hepatitis C virus in North America, Europe and Japan, and hepatitis B virus in China, South Korea and Taiwan. The most common Barcelona Clinic Liver Cancer stage at diagnosis was C in North America, Europe, China and South Korea, and A in Taiwan and Japan. Across all stages, first HCC treatment was most frequently transarterial chemoembolization in North America, Europe, China and South Korea, percutaneous ethanol injection or radiofrequency ablation in Japan and resection in Taiwan. Survival from first HCC treatment varied significantly by region, with median overall survival not reached for Taiwan and 60, 33, 31, 24 and 23 months for Japan, North America, South Korea, Europe and China respectively ( P < 0.0001). Conclusions Initial results from the BRIDGE study confirm previously reported regional trends in patient demographic characteristics and HCC risk factors, document the heterogeneity of treatment approaches across regions/countries and underscore the need for earlier HCC diagnosis worldwide.
The role of hepatic resection in the treatment of hepatocellular cancer
Roayaie, Sasan , Jibara, Ghalib , Tabrizian, Parissa , Yang, Jijin , Yan, Lünan, Schwartz, Myron , Han, Guohong , Izzo, Francesco , Chen, Mishan, Blanc, Jean‐Frédéric , Kudo, Masatoshi , Roberts, Lewis R. , Sherman, Morris , Park, Joong‐Won , Johnson, Philip J. , Roberts, Lewis R , Kudo, Masatoshi

Mayo Clinic

Hepatology | February 12, 2015 | Volume: 62 | Issue: 2 | Pages: 440-451

10.1002/hep.27745 | PMID 25678263 Get It

Current guidelines recommend surgical resection as the primary treatment for a single hepatocellular cancer (HCC) with Child's A cirrhosis, normal serum bilirubin, and no clinically significant portal hypertension. We determined how frequently guidelines were followed and whether straying from them impacted survival. BRIDGE is a multiregional cohort study including HCC patients diagnosed between January 1, 2005 and June 30, 2011. A total of 8,656 patients from 20 sites were classified into four groups: (A) 718 ideal resection candidates who were resected; (B) 144 ideal resection candidates who were not resected; (C) 1,624 nonideal resection candidates who were resected; and (D) 6,170 nonideal resection candidates who were not resected. Median follow‐up was 27 months. Log‐rank and Cox's regression analyses were conducted to determine differences between groups and variables associated with survival. Multivariate analysis of all ideal candidates for resection (A+B) revealed a higher risk of mortality with treatments other than resection. For all resected patients (A+C), portal hypertension and bilirubin >1 mg/dL were not associated with mortality. For all patients who were not ideal candidates for resection (C+D), resection was associated with better survival, compared to embolization and “other” treatments, but was inferior to ablation and transplantation. Conclusions : The majority of patients undergoing resection would not be considered ideal candidates based on current guidelines. Not resecting ideal candidates was associated with higher mortality. The study suggests that selection criteria for resection may be modestly expanded without compromising outcomes, and that some nonideal candidates may still potentially benefit from resection over other treatment modalities. (H epatology 2015;62:440–451
Abstract 5358: BRCA1 is a negative modulator of the PRC2 complex.
Zeng, Xianzhou , Chen, Shuai , Wang, Lan , Huang, Haojie

Mayo Clinic

Cancer Research | August 14, 2014 | Volume: 73 | Issue: 8_Supplement | Pages: 5358-5358

10.1158/1538-7445.am2013-5358 Get It

Abstract The Polycomb repressive complex 2 (PRC2) is important for maintenance of stem cell pluripotency and suppression of cell differentiation by promoting histone H3 lysine 27 trimethylation (H3K27me3) and transcriptional repression of differentiation regulatory genes. Here we show that the tumor suppressor protein BRCA1 interacts with EZH2 and other components of PRC2 in mouse embryonic stem (ES) and human breast cancer cells. The BRCA1-binding region in EZH2 overlaps with the non-coding RNA (ncRNA)-binding domain, and BRCA1 expression inhibits the binding of EZH2 to the HOTAIR ncRNA. Decreased expression of BRCA1 causes EZH2 re-targeting genome wide and elevates H3K27me3 levels at PRC2 target loci in both mouse ES and human breast cancer cells. BRCA1 deficiency blocks ES cell differentiation and enhances breast cancer migration and invasion in an EZH2-dependent manner. These results reveal that BRCA1 is a key negative modulator of PRC2 and that loss of BRCA1 inhibits ES cell differentiation and enhances cancer aggressive phenotypes via augmented PRC2 function. Citation Format: Xianzhou Zeng, Shuai Chen, Lan Wang, Haojie Huang. BRCA1 is a negative modulator of the PRC2 complex. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 5358. doi:10.1158/1538-7445.AM2013-5358